Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is Aerie (AERI) Poised for a Beat This Earnings Season?

by Zacks Equity Research

Aerie Pharmaceuticals (AERI) is looking solid on strong prospects of its lead candidate, Rhopressa. We expect investors to focus on further pipeline updates on the third-quarter call.

    Tracey Ryniec headshot

    5 Earnings All-Stars to Start the Week

    by Tracey Ryniec

    With over 1,000 companies reporting, these are some of the best earnings charts to start the week.

      Allergan (AGN) to Report Q3 Earnings: What's in the Cards?

      by Zacks Equity Research

      While Allergan's (AGN) Q3 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.

        Arpita Dutt headshot

        Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling

        by Arpita Dutt

        Johnson & Johnson's (JNJ) Q3 earnings results were the key highlight this week with the company reporting strong results and raising its outlook.

          Company News For Oct 19, 2017

          by Zacks Equity Research

          Companies in the News are: FOGO,ABT,AGN,EA

            Conatus Entrusts Keith W. Marshall With Key Management Roles

            by Zacks Equity Research

            Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.

              Aerie (AERI) Up on FDA Review Committee Result for Rhopressa

              by Zacks Equity Research

              Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa.

                Allergan (AGN) Loses Restasis Patent Lawsuit, Shares Fall

                by Zacks Equity Research

                Allergan (AGN) lost a patent infringement lawsuit filed against companies trying to develop a generic version of its eye drug, Restasis, which is also its second bestselling drug.

                  Non-Alcoholic Steatohepatitis 2017 Progress Update

                  by Zacks Equity Research

                  Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).

                    Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up

                    by Zacks Equity Research

                    Ardelyx's (ARDX) tenapanor reduces abdominal pain and improves bowel movements in a phase III study evaluating the drug in irritable bowel syndrome with constipation.

                      Allergan's Uterine Fibroids Candidate's NDA Accepted by FDA

                      by Zacks Equity Research

                      Allergan plc (AGN) announced that the FDA has accepted the new drug application (NDA) for ulipristal acetate, for the treatment of abnormal uterine bleeding in women with uterine fibroids.

                        United Natural (UNFI) Approves New $200M Share Buyback Plan

                        by Zacks Equity Research

                        United Natural Foods (UNFI) sanctioned new share repurchase program for $200 million in order to boost shareholders' value.

                          Arpita Dutt headshot

                          Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal

                          by Arpita Dutt

                          The FDA approval of Mylan's (MYL) generic version of Teva's Copaxone was the main news this week. Allergan was also in the headlines related to its deal with the Saint Regis Mohawk Tribe.

                            Ryan McQueeney headshot

                            Teva Shares Plummet After Mylan's Copaxone Generic Gets FDA Approval

                            by Ryan McQueeney

                            Shares of Teva Pharmaceuticals (TEVA) opened more than 13% lower on Wednesday, plunging close to their 52-week low in the process. The struggling Israeli pharma firm, which has faced significant pressure to reduce its debt load, is sliding once again--this time because of a brand new competitor.

                              Allergan's Botox Gets FDA Nod for Forehead Line Treatment

                              by Zacks Equity Research

                              Allergan (AGN) secures an FDA approval for Botox Cosmetic product for its third indication of forehead line development.

                                Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA

                                by Zacks Equity Research

                                Allergan (AGN) announced that the FDA has accepted the application for the label expansion of Avycaz to include a new indication and study data.

                                  Allergan (AGN) Pipeline & New Drugs to Counter Generic Woes

                                  by Zacks Equity Research

                                  Allergan's key drugs like Botox/Linzess and new drugs are supporting sales. However, Allergan faces generic threat for Namenda franchise and patent challenges for some other branded drugs.

                                    Will Conatus Liver Disease Candidate Drive Long-Term Growth?

                                    by Zacks Equity Research

                                    Conatus' (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in the company's portfolio are a positive step toward driving growth.

                                      Allergan's (AGN) Vraylar Gets RTF From FDA, New Data for CVC

                                      by Zacks Equity Research

                                      The FDA slaps a refusal-to-file letter on Allergan's (AGN) Vraylar for its supplemental New Drug Application. The company tries to expand the drug???s label for its use as a maintenance treatment.

                                        How is the Age-Related Macular Degeneration Space Faring Now?

                                        by Zacks Equity Research

                                        The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.

                                          Should Value Investors Consider Allergan plc (AGN) Stock Now?

                                          by Zacks Equity Research

                                          Is Allergan (AGN) a great pick from the value investor's perspective right now? Read on to know more.

                                            Amgen/Allergan's Avastin Biosimilar Secures FDA Approval

                                            by Zacks Equity Research

                                            The FDA approves Amgen-Allergan's biosimilar version of Roche's Avastin for treating multiple types of cancers, to be marketed by the trade name of Mvasi.

                                              Biosimilar 2017 Progress Report: Stocks in Focus

                                              by Zacks Equity Research

                                              The biosimilar space remains in the spotlight as a number of regulatory decisions are pending.

                                                AstraZeneca Sells Remaining Rights to its Anaesthetics Drugs

                                                by Zacks Equity Research

                                                AstraZeneca (AZN) recently sold its remaining rights to its anaesthetics medicines to Aspen Group for an upfront consideration of $555 million.

                                                  Ryan McQueeney headshot

                                                  Why Did Teva Pharmaceuticals Stock Soar Today?

                                                  by Ryan McQueeney

                                                  Shares of Teva Pharmaceuticals (TEVA) opened more than 15% higher on Monday after the struggling drugmaker picked H. Lundbeck (HLUYY) chief Kare Schultz to fill its long-vacant CEO role.